129 related articles for article (PubMed ID: 27068183)
21. Structure of bryostatin 20: a symbiont-produced chemical defense for larvae of the host bryozoan, Bugula neritina.
Lopanik N; Gustafson KR; Lindquist N
J Nat Prod; 2004 Aug; 67(8):1412-4. PubMed ID: 15332866
[TBL] [Abstract][Full Text] [Related]
22. Identifying bryostatins and potential precursors from the bryozoan Bugula neritina.
Manning TJ; Land M; Rhodes E; Chamberlin L; Rudloe J; Phillips D; Lam TT; Purcell J; Cooper HJ; Emmett MR; Marshall AG
Nat Prod Res; 2005 Jul; 19(5):467-91. PubMed ID: 15938194
[TBL] [Abstract][Full Text] [Related]
23. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
24. Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.
Loy BA; Lesser AB; Staveness D; Billingsley KL; Cegelski L; Wender PA
J Am Chem Soc; 2015 Mar; 137(10):3678-85. PubMed ID: 25710634
[TBL] [Abstract][Full Text] [Related]
25. An improved source of bryostatin 10, Bugula neritina from the Gulf of Aomori, Japan.
Kamano Y; Zhang HP; Hino A; Yoshida M; Pettit GR; Herald CL; Itokawa H
J Nat Prod; 1995 Dec; 58(12):1868-75. PubMed ID: 8691208
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties.
Andrews IP; Ketcham JM; Blumberg PM; Kedei N; Lewin NE; Peach ML; Krische MJ
J Am Chem Soc; 2014 Sep; 136(38):13209-16. PubMed ID: 25207655
[TBL] [Abstract][Full Text] [Related]
27. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
28. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
29. Potent cytotoxins produced by a microbial symbiont protect host larvae from predation.
Lopanik N; Lindquist N; Targett N
Oecologia; 2004 Mar; 139(1):131-9. PubMed ID: 14747940
[TBL] [Abstract][Full Text] [Related]
30. Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3β.
Wang J; Wang Z; Sun Y; Liu D
Biochem Biophys Res Commun; 2019 May; 512(3):473-478. PubMed ID: 30904158
[TBL] [Abstract][Full Text] [Related]
31. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.
Wender PA; Hardman CT; Ho S; Jeffreys MS; Maclaren JK; Quiroz RV; Ryckbosch SM; Shimizu AJ; Sloane JL; Stevens MC
Science; 2017 Oct; 358(6360):218-223. PubMed ID: 29026042
[TBL] [Abstract][Full Text] [Related]
32. Chemoenzymatic Dissection of Polyketide β-Branching in the Bryostatin Pathway.
Slocum ST; Lowell AN; Tripathi A; Shende VV; Smith JL; Sherman DH
Methods Enzymol; 2018; 604():207-236. PubMed ID: 29779653
[TBL] [Abstract][Full Text] [Related]
33. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
34. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
36. Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships.
Kedei N; Kraft MB; Keck GE; Herald CL; Melody N; Pettit GR; Blumberg PM
J Nat Prod; 2015 Apr; 78(4):896-900. PubMed ID: 25808573
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
38. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
39. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.
Ryckbosch SM; Wender PA; Pande VS
Nat Commun; 2017 Feb; 8(1):6. PubMed ID: 28232750
[TBL] [Abstract][Full Text] [Related]
40. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.
De Lorenzo MS; Yamaguchi K; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Oct; 9(13):5036-43. PubMed ID: 14581379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
